• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Biomerica Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    12/17/24 5:00:35 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BMRA alert in real time by email
    false 0000073290 0000073290 2024-12-13 2024-12-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    FORM 8-K

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 13, 2024

     

    BIOMERICA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37863   95-2645573

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    17571 Von Karman Ave. Irvine, California   92614
    (Address of Principal Executive Offices)   (Zip Code)

     

    (949) 645-2111

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $.08   BMRA   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    Biomerica, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) on December 13, 2024, at its corporate headquarters in Irvine, California. As of October 16, 2024, the record date for the 2024 Annual Meeting, the Company had 16,821,646 shares of common stock outstanding and entitled to vote, of which 10,287,675 shares of common stock were present in person or represented by proxy and entitled to vote at the 2024 Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2024 Annual Meeting.

     

    Proposal No. 1: The Company’s stockholders elected each of the five nominees named below to serve on the Company’s Board of Directors (the “Board”) until the next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or her earlier resignation, death or removal.

     

    Nominee  Votes For   Votes Withheld   Broker Non-votes 
    Zackary Irani   4,784,611    169,339    5,524,703 
    Allen Barbieri   4,757,823    196,127    5,524,703 
    Jane Emerson, M.D., Ph.D.   4,611,714    342,236    5,524,703 
    Catherine Coste   4,779,659    174,291    5,524,703 
    David Moatazedi   4,772,930    181,020    5,524,703 

     

    Proposal No. 2: The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to our named executive officers.

     

    Votes For   Votes Against   Votes Abstaining   Broker Non-Votes 
     4,613,080    275,661    65,209    5,524,703 

     

    Proposal No. 3: The Company’s stockholders ratified the selection of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending May 31, 2025.

     

    Votes For   Votes Against   Votes Abstaining   Broker Non-Votes 
     10,287,675    94,547    96,431    — 

     

    Proposal No. 4: The Company’s stockholders approved the 2024 Stock Incentive Plan.

     

    Votes For   Votes Against   Votes Abstaining   Broker Non-Votes 
     4,186,308    730,217    37,425    5,524,703 

     

    Proposal No. 5: The Company’s stockholders approved the amendment to the Company’s First Amended and Restated Certificate of Incorporation to authorize the Board, at their discretion, to effect a reverse stock split of the Company’s common stock.

     

    Votes For   Votes Against   Votes Abstaining   Broker Non-Votes 
     9,789,531    558,553    130,569    — 

     

    Proposal No. 6: The Company’s stockholders approved the amendment to the Company’s First Amended and Restated Certificate of Incorporation to authorize the Board, at their discretion, to effect an increase in the number of authorized shares of the Company’s common stock.

     

    Votes For   Votes Against   Votes Abstaining   Broker Non-Votes 
     9,619,013    770,675    88,965    — 

     

    Proposal No. 7: The Company’s stockholders approved an adjournment of the Annual Meeting, if necessary or appropriate, including to establish a quorum.

     

    Votes For   Votes Against   Votes Abstaining   Broker Non-Votes 
     9,905,692    360,840    212,121    — 

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BIOMERICA, INC.
         
    Date: December 17, 2024 By: /s/ Zackary S. Irani
        Zackary S. Irani
        Chief Executive Officer

     

     

    Get the next $BMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BMRA
    SEC Filings

    See more
    • Biomerica Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BIOMERICA INC (0000073290) (Filer)

      4/16/25 9:00:09 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Biomerica Inc.

      10-Q - BIOMERICA INC (0000073290) (Filer)

      4/14/25 4:15:33 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Biomerica Inc.

      10-Q - BIOMERICA INC (0000073290) (Filer)

      1/14/25 5:06:05 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System

      Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomesPrecision Medicine: inFoods® IBS identifies specific individual food triggers that can cause IBS symptoms (bloating, pain, diarrhea, and constipation) offering a personalized, non-drug solution IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today anno

      5/22/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement

      - Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the American Medical Association (AMA) CPT Editorial Panel requesting the assignment of a Proprietary Laboratory Analysis (PLA) code for the inFoods® IBS diagnostic test. If granted, the PLA

      5/7/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Detection of H. pylori Infection

      10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerApproximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogenThis test empowers healthcare providers with fast, accessible testing across the UAE IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced today that its Fortel® Ulcer Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory approval enables Biomerica to introduce its rapid point-of-care test for Heli

      4/23/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biomerica Inc.

      SC 13G/A - BIOMERICA INC (0000073290) (Subject)

      11/14/24 4:19:51 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Biomerica Inc. (Amendment)

      SC 13G/A - BIOMERICA INC (0000073290) (Subject)

      2/14/24 9:00:06 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Biomerica Inc.

      SC 13G - BIOMERICA INC (0000073290) (Subject)

      2/9/24 3:06:57 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Financials

    Live finance-specific insights

    See more
    • Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

      InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting  Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs  Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q  Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products, today reported its second quarter fiscal 2023 fina

      1/13/23 6:39:00 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

      IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, "LabCorp" (NYSE:LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world's largest diagnostics clinical laboratories, boasting $7B in annual revenues, ov

      2/21/24 8:19:00 AM ET
      $BMRA
      $LH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Medical Specialities
    • Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica

      Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to serve as the Chairman of the Board of Directors of Biomerica. Mr. Zack Irani will continue to serve as CEO. Mr. Kenny joined the Biomerica Board of Director

      1/23/24 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Diagnostics Industry Leader Jack Kenny Joins Biomerica's Board of Directors

      Kenny has proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian BioscienceAs CEO Kenny managed the sale of Meridian Biosciences in an all-cash transaction valued at approximately $1.53 billion NEWPORT BEACH, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors. Meridian Biosciences (formerly traded on Nasdaq under VIVO) is a leadin

      8/28/23 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Emerson Jane was granted 85,000 shares, increasing direct ownership by 120% to 156,000 units (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:09 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Coste Catherine was granted 85,000 shares, increasing direct ownership by 194% to 128,790 units (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:05 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Moatazedi David was granted 85,000 shares (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:07 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care